<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781898</url>
  </required_header>
  <id_info>
    <org_study_id>808422</org_study_id>
    <secondary_id>R01DA024553</secondary_id>
    <nct_id>NCT00781898</nct_id>
  </id_info>
  <brief_title>Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site</brief_title>
  <official_title>Prevention of Relapse to Opioid Addiction Using Depot Naltrexone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to conduct a multi-site effectiveness study to determine whether
      the addition of a monthly injection of depot naltrexone to treatment as usual (TAU) will
      significantly improve outcome in parolees and probationers with a history of opioid addiction
      compared to TAU alone. Participants will be randomized to either treatment as usual in
      community programs or monthly injections of depot naltrexone for six months with treatment as
      usual in community programs. The effectiveness of depot naltrexone has never been studied in
      opioid dependent parolees. all parolee subjects will be evaluated at baseline, while in
      treatment, and at 6, 12 and 18 month post entry time points. The primary study outcomes are
      retention in treatment, drug use, re-arrests, psychosocial and medical/psychiatric
      functioning, and economic costs and benefit costs of naltrexone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This site serves as the coordinating center for five sites conducting the trial under the
      same IND and same protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse</measure>
    <time_frame>6 months</time_frame>
    <description>A relapse event was defined as 10 or more days of opioid use in a 28-day (4-week) period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Opiate Addiction</condition>
  <arm_group>
    <arm_group_label>Depot Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot naltrexone</intervention_name>
    <description>VivitrolÂ® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.</description>
    <arm_group_label>Depot Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as Usual (TAU)</intervention_name>
    <description>Treatment as Usual (TAU) community treatment provided to the participant</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be between the ages of 18 and 60;

          -  Have dx of opioid dependence according to DSM-IV criteria

          -  be in good general health as determined by complete physical and laboratory tests;

          -  Under some form of criminal justice supervision for at least 12 months;

          -  Have a negative result for urinary opioids and no sign of opiate withdrawal after IV
             (or IM) injection of 0.8 mg of naloxone; and

          -  Express a goal of opiate free treatment rather than agonist maintenance

        Exclusion Criteria:

          -  Current drug or alcohol dependence that requires medical supervision;

          -  untreated psychiatric disorders that might make participation hazardous (e.g.
             untreated psychosis, bipolar disorder with mania, significant suicide risk).
             Adequately treated psychiatric disorders and appropriate psychotropic medications
             would be allowed.

             3. Active medical illness that might make participation hazardous (e.g., untreated
             hypertension, hepatitis with AST or ALT &gt;3 times upper limit of normal, unstable
             diabetes or heart disease). Adequately treated medical conditions are acceptable; 4.
             female subjects who are pregnant or lactating, or female subjects of childbearing
             potential who are not using birth control (oral contraceptives, barrier (diaphragm or
             condom) plus spermicide, or levonorgestriel implant); 5. Liver failure or liver
             function test levels greater than three times normal; 6. History of allergic reaction
             to naltrexone; 7. History of a drug overdose in the past 3 years; and 8. Current
             diagnosis of chronic pain disorder for which opioids are prescribed for pain relief.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles P O'Brien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James W Cornish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna Coviello, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Friedmann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Kinlock, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mountain Manor Treatment Center, Baltimore MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward B. Nunes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josh Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University/Bellevue</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>September 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2017</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depot naltrexone</keyword>
  <keyword>Parolees</keyword>
  <keyword>Opioid addiction prevention</keyword>
  <keyword>Medication Treatment Alternatives</keyword>
  <keyword>Prevention of Relapse to Opioid Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Community-dwelling adult volunteers who had been incarcerated and who had a history of opioid dependence.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Depot Naltrexone</title>
          <description>Depot naltrexone: VivitrolÂ® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Treatment as Usual (TAU): Treatment as Usual (TAU) community treatment provided to the participant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants in this arm were randomized to Depot Nalttrexone (Extended Release Naltrexone)</population>
      <group_list>
        <group group_id="B1">
          <title>Depot Naltrexone</title>
          <description>Participants who were randomized to receive Extended Release Naltrexone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Treatment as Usual (TAU): Treatment as Usual (TAU) community treatment provided to the participant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="9.2"/>
                    <measurement group_id="B2" value="43" spread="9.4"/>
                    <measurement group_id="B3" value="43.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse</title>
        <description>A relapse event was defined as 10 or more days of opioid use in a 28-day (4-week) period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depot Naltrexone</title>
            <description>Depot naltrexone: VivitrolÂ® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment as Usual (TAU): Treatment as Usual (TAU) community treatment provided to the participant</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse</title>
          <description>A relapse event was defined as 10 or more days of opioid use in a 28-day (4-week) period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Adverse Events were assessed at each study visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Depot Naltrexone</title>
          <description>Depot naltrexone: VivitrolÂ® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treatment as Usual (TAU): Treatment as Usual (TAU) community treatment provided to the participant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nonfatal Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Exacerbation of Pre-existing condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Any Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fatal Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Opioid Withdrawal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hospitalization Unknown</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal symptom</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression or suicidality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery for Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charle P. O'Brien</name_or_title>
      <organization>University Of Pennsylvania</organization>
      <phone>215-222-3200</phone>
      <email>obrien@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

